Diagnosis, progression patterns and prognostication in mastocytosis
Wolfgang R Sperr1, Peter Valent
1Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria. wolfgang.r.sperr@meduniwien.ac.at
Expert Review of Hematology
|July 12, 2012
Summary
Mastocytosis involves abnormal mast cell growth. While childhood cases often resolve, adult systemic mastocytosis persists, with prognosis varying from indolent to advanced forms requiring further study of prognostic factors.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Mastocytosis is a disorder characterized by abnormal mast cell proliferation.
- Childhood mastocytosis (CM) is common and often self-limiting, while adult systemic mastocytosis (ASM) is persistent.
- The KIT D816V mutation is prevalent in adult ASM, influencing disease course.
Purpose of the Study:
- To review current understanding of mastocytosis.
- To discuss prognostic parameters for indolent and advanced systemic mastocytosis.
- To highlight the need for better prediction of individual patient outcomes.
Main Methods:
- Review of current literature on mastocytosis.
- Analysis of World Health Organization (WHO) classification criteria.
- Examination of prognostic factors in indolent and advanced mastocytosis.
Main Results:
- Mastocytosis presents heterogeneously, with distinct pediatric and adult forms.
- Adult systemic mastocytosis is often associated with the KIT D816V mutation.
- Prognosis varies significantly, from stable indolent disease to less favorable advanced forms.
Conclusions:
- Mastocytosis requires careful prognostic assessment, especially in adults.
- Further research into specific prognostic factors is crucial for personalized patient management.
- Understanding prognostic parameters aids in differentiating disease trajectories and informing treatment strategies.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...